STOCK TITAN

Insider to sell 266 Vertex (VRTX) shares valued at 133000.00

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Vertex Pharmaceuticals has an insider planning a modest stock sale. A person associated with Vertex intends to sell 266 shares of common stock through Fidelity Brokerage Services on the NASDAQ, with an aggregate market value of 133000.00, around 02/13/2026.

The 266 shares were acquired on 05/01/2024 through restricted stock vesting as compensation from the issuer. Vertex had 253,718,831 shares of common stock outstanding, which is a baseline figure for the company’s total share count.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the latest Form 144 for VRTX disclose?

The notice discloses that an insider related to Vertex Pharmaceuticals plans to sell 266 shares of common stock. The sale is expected to occur on or about 02/13/2026 through Fidelity on the NASDAQ exchange.

How many Vertex (VRTX) shares are planned to be sold under this Form 144?

The Form 144 shows a planned sale of 266 shares of Vertex common stock. The aggregate market value listed for this block is 133000.00, indicating a relatively small transaction compared with the company’s total outstanding shares.

How were the VRTX shares in this Form 144 originally acquired?

The 266 Vertex shares were acquired on 05/01/2024 through restricted stock vesting. The filing states they were received from the issuer as compensation, rather than purchased for cash in the open market.

What is the aggregate market value of the VRTX shares to be sold?

The Form 144 lists an aggregate market value of 133000.00 for the 266 Vertex shares. This value reflects the estimated total dollar amount of the planned sale through Fidelity Brokerage Services on the NASDAQ exchange.

How many Vertex (VRTX) shares are outstanding in this Form 144?

The filing reports 253,718,831 shares of Vertex common stock outstanding. This figure provides context for the company’s total share base and helps investors gauge the relative size of the planned 266-share sale.

What type of transaction is reported for the VRTX shares in this Form 144?

The transaction involves restricted stock vesting that occurred on 05/01/2024, classified as compensation from the issuer. The Form 144 then covers the proposed resale of those vested shares through a broker on NASDAQ.
Vertex Pharmaceuticals Inc

NASDAQ:VRTX

VRTX Rankings

VRTX Latest News

VRTX Latest SEC Filings

VRTX Stock Data

124.70B
253.12M
0.14%
98.18%
1.42%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON